External validation of a novel electronic risk score for cancer‐associated thrombosis in a comprehensive cancer center

Abstract

Venous thromboembolism (VTE) is a significant complication for cancer patients undergoing systemic therapy. We performed an independent external validation for a recently derived and validated a novel electronic health record (EHR) VTE risk score in a comprehensive cancer center. Adult patients with incident cancer diagnoses were identified from MD Anderson Cancer Center Tumor Registry 1/2017-1/2021. Baseline covariates extracted at the time of first-line systemic therapy included demographics, cancer site/histology, stage, treatment, complete blood count, body mass index, recent prolonged hospitalization, and history of VTE or paralysis. VTE was ascertained using an institution-specific natural language processing radiology algorithm (positive predictive value of 94.8%). The median follow-up for 21 142 cancer patients was 8.1 months. There were 1067 (5.7%) VTE within 6 months after systemic therapy. The distribution of the novel score for 0-

Lower-extremity deep vein thrombosis induced by oxaliplatin and capecitabine chemotherapy: A case report

“…Implementing an exhaustive VTE risk assessment prior to chemotherapy initiation is essential, and the Khorana scoring system can be utilized to ascertain VTE risk among patients with cancer treated with chemotherapy. 21 This evaluation encompasses the cancer type, therapeutic regimen, and individual risk factors, including age, body mass, and VTE history. Established clinical practice guidelines delineate the management of cancer-associated VTE, advocating for prophylactic anticoagulation in individuals who are identified as high risk.…”

Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention

“…A score > 2 is associated with a very high venous thromboembolism risk (Table 2) [81]. A further model was developed very recently by the Harris Health System and externally validated by the Veterans Affairs healthcare system [82], and then externally validated by MD Anderson Cancer Center Tumor Registry [88]. The score considered specific factors related to cancer stage and risks associated with treatment, as well as predictors of venous thromboembolism, such as the history of venous thromboembolism, history of paralysis/immobility, recent hospitalization, and Asian Pacific Islander race (conferring a decreased venous thromboembolism risk).…”

“…The score considered specific factors related to cancer stage and risks associated with treatment, as well as predictors of venous thromboembolism, such as the history of venous thromboembolism, history of paralysis/immobility, recent hospitalization, and Asian Pacific Islander race (conferring a decreased venous thromboembolism risk). Six risk categories can be obtained on the basis of the total score, which can be dichotomized into low risk (score 0, 1 or 2) or high risk (3, 4 or 5) (Table 2) [82]. This model had improved performance over the Khorana score (c-statistic, 0.71 vs. 0.65, respectively, for the new risk assessment model and Khorana score) and doubled the number of venous thromboembolism events in the high-risk stratum [82].…”

“…Six risk categories can be obtained on the basis of the total score, which can be dichotomized into low risk (score 0, 1 or 2) or high risk (3, 4 or 5) (Table 2) [82]. This model had improved performance over the Khorana score (c-statistic, 0.71 vs. 0.65, respectively, for the new risk assessment model and Khorana score) and doubled the number of venous thromboembolism events in the high-risk stratum [82].…”